Bessi et al. used an NSG panel targeting 6 selected genes (B2M, STAT6, XPO1, NFKBIE, PTPN1, and TNFAIP3) to compare the mutational spectrum of matched tissue biopsies and plasma collected before treatment in 24 cHL patients. This evidence concerns the gene TNFAIP3 and classic Hodgkin lymphoma.